

## **Blue Star Opportunities confirms continuing operating growth with Q2 operating results 72% higher than 2<sup>nd</sup> quarter 2023.**

RENO, NV. August 28<sup>th</sup>, 2024. **Blue Star Opportunities Corp.** (The "Company") (OTC: **BSTO**), is pleased to report sharp growth in both top and bottom lines for the second quarter fiscal 2024. Gross revenue from operations was more than 100% over the first quarter and 71% over the same quarter a year ago. Full details is available in our Quarterly Disclosure Statement at [BSTO - Blue Star Opportunities Corp. | Overview | OTC Markets](#)

Revenue growth is expected to continue accelerating due to the use of intelligent marketing tools that are proving to be extremely effective. Further revenue guidance will be provided at the beginning of September.

The Company is also reporting good progress toward the future launch of its Diomedes AI application for the prevention of medical errors. Our Diomedes MedGuard is a clinical solution for preventing medication errors that was first developed at the McGill University Health Center where it managed to reduce drug errors by 80% and mortality by 50%. With current progress in AI the same effective intelligence can now be offered through an AI driven app directly to consumers who wish to protect themselves from adverse drug events which according to the NIH remains highly concerning. More information on Diomedes can be found at [www.bstoai.com](http://www.bstoai.com)

The Company continues to work on developing more intelligent applications to bring efficiency to clinical work. Some of this work showcasing our AI expertise and clinical know how can be sampled in a video by following the link below.

<https://www.youtube.com/watch?v=gYur6lBg6CY&t=7s>

### **About Blue Star Opportunities Corp**

Blue Star Opportunities Corp (OTC BSTO) deploys a deep bench of knowledge and expertise in developing AI driven systems for solving critical issues impacting people's health. The company's AI driven innovative solutions include apps for individuals to protect themselves against potentially deadly prescription errors, allergies and undesirable reactions. Our latest generation Diomedes applications provide online real time protection against prescription and over-the-counter drug risks. The company also continues to derive most of its revenues from its legacy business of renewable high-end cork flooring. We are also one of the first companies in the world to spearhead the next generation of new, more potent nutraceuticals to promote health through human immune optimization. The recent Covid pandemic has highlighted the need to identify new natural extracts to assist humans optimize their immune systems to better cope with unwelcome invasions by a variety of new pathogens.

**FORWARD-LOOKING STATEMENTS:** Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Company products and services, the impact of price pressures exerted

by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

**Media Contact: 438-501-6500**